Scott Alexander summarizes and responds to various criticisms of meritocracy from commenters, arguing that despite its flaws, meritocracy is preferable to alternatives like cronyism. Longer summary

This post discusses various criticisms and concerns about meritocracy raised in the comments of a previous article. Scott Alexander summarizes and responds to several key points, including the definition of meritocracy, its application in different fields, potential negative consequences, and alternatives. He addresses concerns about meritocracy creating a disconnected elite class, stripping lower classes of leadership, and the challenges of truly implementing a merit-based system. Scott argues that while meritocracy has flaws, it's still preferable to alternatives like cronyism, and criticizes some anti-meritocracy arguments as being utopian or impractical. Shorter summary

Scott Alexander argues that the EpiPen price hike is due to over-regulation and cronyism in the pharmaceutical industry, not lack of regulation as suggested by Vox. Longer summary

This post criticizes Vox's article on EpiPen price hikes, arguing that the problem isn't lack of regulation but over-regulation and cronyism. Scott Alexander contrasts the pharmaceutical industry with the unregulated chair industry, pointing out that chair prices don't suddenly spike 400%. He then details how FDA regulations and patent laws prevent competitors from entering the EpiPen market, despite the drug being off-patent and inexpensive to produce. The post highlights several failed attempts by companies to create generic versions of EpiPens, and how lobbying by the manufacturer Mylan has helped maintain their monopoly. Scott uses an extended analogy comparing the situation to a hypothetical government-controlled chair market to illustrate the absurdity of the current system. Shorter summary